(Press-News.org) John Kempen, MD, MPH, PhD, MHS, Director of Epidemiology for Ophthalmology at Mass Eye and Ear and Harvard Medical School, is the lead author of a paper published in The Lancet Global Health, “Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia.”
Q: Why is trachoma important?
Trachoma is the leading cause of infectious blindness in the world, predominantly affecting low-income individuals, and women more than men. It’s most common in Africa, with Ethiopia being the most affected country.
Trachoma causes scarring on the ocular surface, including the inner surface of the eyelids. The latter causes the eyelashes to turn in, scratching the cornea and leading to blindness through corneal damage and secondary infections. Thus, it not only causes blindness, but also constant misery with the lashes always scratching on the corneal surface.
The World Health Organization (WHO) has established a plan to try to clear blindness from trachoma, in part by conducting surgery on eyes with inturned upper eyelashes (a condition known as trachomatous trichiasis, or “TT”). Because it’s not uncommon for TT surgery to fail, which is hard to fix, improving the outcomes of surgery is very important. The FLAME Trial is part of an initiative to improve the quality of surgery to better prevent blindness and improve quality of life for those affected.
Q: How would you summarize your study for a lay audience?
The FLAME Trial was a large-scale field trial in Ethiopia designed to confirm (or refute) the impressive results from a preliminary trial comparing three doses of a low-risk, topical anti-inflammatory treatment called fluorometholone to placebo. In this initial trial, all three groups experienced about a one-third reduction in the risk of postoperative TT.
However, as our new study reports, the FLAME trial could not confirm the promising preliminary results. Given the far larger sample size of FLAME, we are confident in its “negative” results, and interpret them to mean that anti-inflammatory therapy is unlikely to advance this field.
Q: What question were you investigating and how did you approach answering it?
We were evaluating whether fluorometholone 0.1% suspension given just before surgery and postoperatively for 4 weeks would reduce the risk of recurrence of postoperative TT.
Our study, which was supported by the National Eye Institute of the NIH, was a randomized controlled clinical trial in which more than 2,400 participants received an active or placebo (artificial tears) treatment. Because this disease affects very disadvantaged individuals in remote areas, our research team would often travel on motorcycles—or even walk—to the remote sites where surgeries were performed. The study also gave us an opportunity to provide free treatment to nearly 3,000 people (including those presenting for care who did not qualify for or consent to study enrollment).
Q: What did you find, and what are the implications of the results?
Our results convincingly showed no difference between the active fluorometholone treatment and placebo, with near-identical results between groups. In terms of safety, results were similar as well, suggesting that taking fluorometholone twice daily for 4 weeks is generally safe. That is an important finding for the use of fluorometholone for other diseases.
The results, along with negative results from a different trial, suggest that the use of anti-inflammatory therapy along with all surgeries is not likely to help improve TT surgery outcomes. However, because of the rich dataset we accumulated, we plan to conduct additional, secondary analyses.
Q: What are the next steps?
It will be best to shift focus to other ideas for improving TT surgery outcomes, and there are some promising new opportunities. A published secondary analysis from the FLAME Trial has found that the results of one of the two WHO-endorsed surgical techniques has about 70% less recurrent or postoperative TT. This confirmed results from a previous clinical trial showing about a 50% reduction in postoperative TT with the “Posterior Lamellar Tarsal Rotation” (PLTR) technique (also known as the Trabut technique) than with the “Bilamellar Tarsal Rotation” technique.
In addition, our group has also shown that refresher training in a structured supportive mentorship context can reduce the risk of postoperative TT substantially.
In general, focusing on quality assurance for TT surgery seems to be the key concept to make outcomes as favorable as possible. General preventive efforts targeting antibiotics, face washing and environmental improvement also remain very important.
Authorship: In addition to Kempen, Mass General Brigham authors include Ahlam Awad Mohammed. Additional authors included Aida Abashawl, Sarity Dodson, Wondu Alemayehu, Fangming Jin, Alemu Gemechu, Aemero Abateneh Mengesha, Dereje Adugna Kumsa, Yineng Chen, Kathleen McWilliams, Berhanu Tulu, Genemo Abdela, Alemayehu Megersa, Tolossa Cheru, Gadisa Mohammad, Tony Succar, Vatinee Y Bunya, K Davina Frick, Maureen G Maguire, Matthew J Burton, and Gui-Shuang Ying of the Center for Preventive Ophthalmology and Biostatistics of the University of Pennsylvania, which has the FLAME trial data repository.
Paper cited: Kempen JH, et al. “Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia.” Lancet Global Health. DOI: 10.1016/S2214-109X(25)00493-0
Funding: This study was supported by National Eye Institute (NIH) grants (UG1EY030420 for Chair grant) and (UG1EY030419 for Data Center grant). Additional funding was from the Mass Eye and Ear Global Surgery Program, Sight for Souls and Research to Prevent Blindness. The FLAME Trial received donations of fluorometholone 0.1% suspension brand name FML from Allergan (an AbbVie company; Dublin, Ireland) as the active treatment for the study.
END
Clinical trial in Ethiopia targets the trachoma scourge
2026-01-13
ELSE PRESS RELEASES FROM THIS DATE:
Open-sourcing the future of food
2026-01-13
For the last two years, the cultivated meat industry has been experiencing growing pains. Many startups have shrunk, shut down, or pivoted. Their advances aren’t going to waste, though.
The Tufts University Center for Cellular Agriculture (TUCCA), which seeks to enable production of meat, milk, and eggs from cells instead of animals, has teamed up with nonprofit partner Good Food Institute to salvage the intellectual property—the inventions—of those firms and make them publicly available to help nurture the industry.
Specifically, this effort aims to obtain and broadly distribute cell lines—cells of a specific type ...
Changes in genetic structure of yeast lead to disease-causing genomic instabilities
2026-01-13
Osaka, Japan – Changes in genes have been linked to the development of different diseases for a while. However, it’s not exactly clear what the mechanisms, or the causes behind those specific genetic changes, are. Recent studies using fission yeast, which can act as an ideal model for human cells, have highlighted one possible mechanism linked to disease onset.
In a study recently published in Nucleic Acids Research, researchers from The University of Osaka discovered that the loss of heterochromatin ...
UC San Diego Health Sciences Grant Writing Course helps launch successful research careers
2026-01-12
To launch a successful research career in the health sciences, junior faculty need to write persuasive, high-quality grant proposals that get funded. However, the skill is not widely taught in medical schools or graduate programs. In a new study, University of California San Diego researchers report that early career faculty who completed the institution’s innovative Health Sciences Grant Writing Course demonstrated significant increases in grant submission rates and funding success — especially among women and faculty ...
Study: Many head and neck cancer trials end early. Why?
2026-01-12
MIAMI, FLORIDA (Jan. 12, 2026) – Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most common reasons are sponsor decisions related to safety or effectiveness and poor patient recruitment.
Researchers from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators analyzed 692 clinical trials launched between 2000 and 2024. Alex Reznik, M.D./Ph.D. student at the University of Miami and co-author, described the study as “A retrospective query of head and neck cancer clinical trials in which we compared ...
Tufts vice provost for research named Foreign Fellow of Indian National Science Academy
2026-01-12
Bernard Arulanandam, vice provost for research at Tufts University and professor of immunology at Tufts University School of Medicine, has been named a foreign fellow of the Indian National Science Academy. This honor recognizes his significant contributions to scientific research and his longstanding engagement with international scientific communities.
The Indian National Science Academy, established in 1935, is India’s premier scientific body dedicated to advancing scientific inquiry ...
New model improves prediction of prostate cancer death risk
2026-01-12
Embargoed for release until 5:00 p.m. ET on Monday 12 January 2026
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing ...
Two wrongs make a right: how two damaging variants can restore health
2026-01-12
Seattle, WA — In a groundbreaking study published in the in Proceedings of the National Academy of Sciences (PNAS), scientists at Pacific Northwest Research Institute (PNRI) have overturned a long-held belief in genetics: that inheriting two harmful variants in the same gene always worsens disease. Instead, the team found that, in many cases, two harmful variants can actually restore normal protein function.
The research focused on a human enzyme called argininosuccinate lyase (ASL), ...
Overlooked decline in grazing livestock brings risks and opportunities
2026-01-12
For decades, researchers have focused on the problem of overgrazing, in which expanding herds of cattle and other livestock degrade grasslands, steppes and desert plains. But a new global study reveals that in large regions of the world, livestock numbers are substantially declining, not growing — a process the authors call destocking.
“We often assume that rangelands are being degraded because we overgraze them, but the data show that it's not the whole story: nearly half of livestock production occurs in areas that have experienced destocking over the past 25 years,” said study co-author Osvaldo Sala, an ecologist and professor ...
Using rare sugars to address alcoholism
2026-01-12
Kyoto, Japan -- While investigating the FGF21-oxytocin-dopamine system, a mechanism that regulates sugar appetite, a team of researchers at Kyoto University noticed reports suggesting that the protein FGF21 may regulate alcohol ingestion. The team's original aim had been to address sugar appetite in lifestyle-related diseases, but since alcohol is a fermented product of sugar, they speculated that perhaps the body contains a system that recognizes both alcohol and sugar as the same entity.
Excessive alcohol consumption is a major global health issue, and ...
Research alert: New vulnerability identified in aggressive breast cancer
2026-01-12
Researchers at University of California San Diego have identified a previously unrecognized treatment target for triple‑negative breast cancer (TNBC), the most aggressive subtype of breast cancer. Their new study reveals that a protein called PUF60 plays an essential role in helping TNBC cells grow and survive by controlling how key genes are spliced. In models of TNBC, disrupting the activity of PUF60 caused widespread errors in gene processing, resulting in DNA damage, cell‑cycle arrest and ultimately tumor cell death. ...